Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
about
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerLong Non-coding RNAs in Urologic Malignancies: Functional Roles and Clinical TranslationProstate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal BiomarkersThe novel prostate cancer antigen 3 (PCA3) biomarker.Long noncoding RNAs as putative biomarkers for prostate cancer detection.A multiplex assay to measure RNA transcripts of prostate cancer in urine.BMCC1 is an AP-2 associated endosomal protein in prostate cancer cellsPCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experienceOncogenic activation of ERG: A predominant mechanism in prostate cancer.Role of active surveillance in the management of localized prostate cancer.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewMarkers for detection of prostate cancer.Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Novel biomarkers for the detection of prostate cancer.Tumour markers in prostate cancer III: biomarkers in urine.Emerging biomarkers of prostate cancer (Review)Toward the detection of prostate cancer in urine: a critical analysis.PCA3 in the detection and management of early prostate cancer.Urinary biomarkers for prostate cancer: a review.Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis.How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer.Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer.Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.Current biomarkers for diagnosing of prostate cancer.PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocolsExternal validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.The role of prostate cancer biomarkers in undiagnosed men.The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy.Progensa™ PCA3 test for prostate cancer.The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
P2860
Q26784517-F704F7EA-FD38-4081-95BE-FA8463D0C71DQ28071872-E5C03B8F-EA0C-41DD-8AC6-EA715DF7CF41Q28075610-9C5D90F8-0905-45AD-A2B3-31AC1FCE81F2Q34156075-30E4D9C1-3B61-4FF1-9AA5-ECC0A760C315Q34409743-7722B368-530B-4E1F-9287-E63DF95B4BD8Q34429720-81C21BFD-C7BE-4F22-A5D1-6F8B2DBCBA1CQ34989460-E6A23764-B1CA-4B01-BDE3-8A0B9EECD1E0Q35074229-811E3ABD-F8EB-49F2-8218-B8ECE676B949Q35685920-352B26DB-FABB-4B04-8D98-8F155B9EAA8FQ36520452-6145851B-BE77-4F5C-A8A0-45FE914FA0D1Q36979944-4EFE8608-1B7A-43D8-B7A3-47C89C10D93DQ37328403-EF046236-D3B1-46C1-8574-97145A5496C1Q37629548-A40EE484-1E06-4E45-9E36-CDAC23BE9FC6Q37708174-A995663C-FC5E-4AE0-956C-0F83A69461C0Q37878473-9EAE15DB-20EE-4FF9-9E6E-EC3442F5490AQ38013967-AEC85EDA-BBCC-4133-B496-F150056BC8DFQ38047103-77CCA191-BD09-4460-BA16-3A23279ED490Q38090552-4EC4BA0B-738D-4EDE-BE4B-20BF7F8B2CE3Q38092578-0B7C58D1-ABB6-465A-862E-90E403DB230CQ38144712-B8D3B918-1D29-41FF-917D-17106260D59AQ38151298-0F6518C9-84B8-4DC3-A3D9-AC3954A51828Q38165242-76C65101-163D-4043-9229-3BBD8A2860DAQ38166577-6C89C13D-779C-4F67-BED3-3C1153BAD2FAQ38191938-6E41D5EF-25DF-456A-960B-7EA5D938E127Q38242279-0D7E3CC9-2C2E-4F2D-A943-60D1C45B6B73Q38403484-00D4643D-FA88-42D9-AE56-14A59FBDDC89Q38568275-9A6AF978-443A-45DB-9997-8CBC1F64D498Q38584370-60D2A70D-8A7B-48CE-A5B6-5D8CB1CB1643Q38656531-00E730F8-5A70-4A65-A08B-968187A30381Q38838706-A48E405F-6F6E-4BB8-AA25-4445C38D7446Q38846321-8AC1843F-C7A7-4328-8CF2-975D0797FCDCQ38854599-F3CC5F3B-4539-4997-A1A6-CF72659E4EBBQ39140686-B0E7D354-2697-4BE0-B784-FE9296D10C7FQ39667433-97E219F9-81B4-47C6-B964-3D8CCAFBB670Q39771683-D05DFE70-B01C-4E0E-ADAA-0AF9FAEE34D8Q39997103-EBC27868-29E0-40E8-8753-0E6A98A50C38Q40211476-64D3F23B-BC4A-4B37-9B16-E8B26E3BDDD5Q40314717-3081D399-2D34-4B20-AA0E-DDC662ED4187Q40706344-64F9818E-00AB-4C84-900A-D4A3431DBD3DQ42659330-8454173F-0D9A-4DF3-8080-4552A3111CB7
P2860
Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@ast
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@en
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@nl
type
label
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@ast
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@en
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@nl
prefLabel
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@ast
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@en
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@nl
P2093
P356
P1433
P1476
Predictive value of PCA3 in ur ...... cteristics of prostate cancer.
@en
P2093
Daphne Hessels
Gerald W Verhaegh
J Alfred Witjes
Jack A Schalken
Martijn P M Q van Gils
Onno van Hooij
Sander A Jannink
P356
10.1002/PROS.21032
P577
2010-01-01T00:00:00Z